To sum up, this study used RM-1 prostate cancer cells as a tumor model, and extracted the RMPs of the tumor cells to be repurposed as drug carriers that encapsulate RSL-3, a ferroptosis inducer targeting GPX-4 which is a key inhibitor of ferroptosis [30]. Here, GPX4 is linked to Familial prostate cancer.